Fluoxetine DR Pellets Manufacturer in India

Fluoxetine DR Pellets Manufacturer in India

Pharmaceutical-Grade Fluoxetine DR Pellets for Delayed-Release Oral Formulations

Fluoxetine DR Pellets are multiparticulate pharmaceutical formulations developed for delayed-release oral dosage applications. The active ingredient is Fluoxetine Hydrochloride, with CAS Number 56296-78-7, molecular formula C₁₇H₁₉ClF₃NO, and molecular weight 345.8 g/mol. PubChem identifies Fluoxetine Hydrochloride as the hydrochloride salt of Fluoxetine.

The SDP pellet product portfolio lists Fluoxetine DR Pellets at 20% strength, providing a defined active-loading option for pharmaceutical formulation development.

The delayed-release pellet format uses a multiparticulate system designed to modify the release of the active ingredient according to the intended formulation profile. Functional coating systems may be incorporated where required to achieve the desired release characteristics.

Key Features

• Fluoxetine delayed-release pharmaceutical pellets
• 20% active ingredient strength
• Pharmaceutical-grade multiparticulate formulation
• Delayed-release formulation platform
• Suitable for oral dosage-form development
• Suitable for capsule-filling applications
• Defined active ingredient loading
• Product-specific quality parameters
• Formulation flexibility
• Suitable for bulk pharmaceutical requirements

Product Information

Fluoxetine Hydrochloride has the molecular formula C₁₇H₁₉ClF₃NO and molecular weight 345.8 g/mol. The CAS Number for Fluoxetine Hydrochloride is 56296-78-7.

Fluoxetine contains a stereogenic center, and the hydrochloride salt exists in stereochemically defined forms. PubChem separately identifies the S- and R-enantiomeric hydrochlorides, so the raw-material specification should clearly identify the applicable material.

For the finished pellet product, the 20% value represents active ingredient loading and should not be confused with the purity assay of Fluoxetine Hydrochloride API.

Available Strength

Fluoxetine DR Pellets — 20%

The 20% strength is listed for Fluoxetine DR Pellets in the referenced pharmaceutical pellet product portfolio.

Applications

Fluoxetine DR Pellets can be considered for:

• Delayed-release oral formulation development
• Multiparticulate pharmaceutical formulations
• Capsule-filling applications
• Modified-release formulation development
• Functional-coated pellet systems
• Oral dosage-form development
• Pharmaceutical formulation development
• Commercial pharmaceutical manufacturing

Why Fluoxetine DR Pellets from Swapnroop?

• Pharmaceutical-Grade Pellets: Designed for pharmaceutical formulation applications.
• 20% Strength: Defined active-loading option for formulation development.
• Delayed-Release Format: Designed for delayed-release multiparticulate applications.
• Multiparticulate Platform: Suitable for pellet-based oral dosage-form development.
• Controlled Release Profile: Functional formulation and coating systems can be used to achieve the required release characteristics.
• Product-Specific Quality Control: Finished pellets can be evaluated against applicable product specifications.
• Capsule-Filling Applications: Suitable for multiparticulate capsule formulation approaches.
• Bulk Pharmaceutical Supply: Suitable for formulation and manufacturing requirements.

Packaging & Supply

Fluoxetine DR Pellets can be supplied in suitable bulk packaging according to customer requirements. Strength, batch quantity, packaging configuration and applicable technical documentation can be specified according to the intended pharmaceutical formulation.

Get Bulk Quote via WhatsApp